Regulus Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Regulus Therapeutics

11/05/2023 22:11

* Regulus Therapeutics Inc  RGLS.OQ  reported a quarterly
adjusted
loss of 42 cents​​ per share for the quarter ended in March. The
mean expectation of three analysts for the quarter was for a
loss of 44 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Regulus Therapeutics Inc's reported EPS for the quarter
was a
loss of 42 cents​.
    * The mean earnings estimate of analysts had risen by
about 16% in
the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * Regulus Therapeutics Inc shares had risen by 77.0% this
quarter and gained 9.5% so far this year.
    * The company reported a quarterly loss of $7.14 million.
    * Wall Street's median 12-month price target for Regulus
Therapeutics Inc is $9.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 09:11 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.44          -0.42          Beat
 Dec. 31 2022      -0.51          -0.40          Beat
 Sep. 30 2022      -0.49          -0.50          Missed
 Jun. 30 2022      -0.48          -0.50          Missed